Insiders who reported open-market trades in the last 12 months at the companies Craig C. Hopkinson files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Craig C. Hopkinson is a corporate insider, tracked as EVP R&D, Chief Medical Officer of Alkermes plc. (ALKS). InsiderAlpha holds 23 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Craig C. Hopkinson submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Craig C. Hopkinson been buying or selling stock?
Recorded transactions: 0 open-market purchases and 21 open-market sales ($8.72M) across all tracked filings.
Craig C. Hopkinson is EVP R&D, Chief Medical Officer of Alkermes plc. (ALKS). 23 SEC Form 4 filings on record going back to 2024, most recently on 1 September 2026. Most recent open-market trade: sold $423K of ALKS on 1 September 2026. Lifetime open-market sales: $8.72M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Craig C. Hopkinson.
InsiderAlpha's records for Craig C. Hopkinson go back to 2024: 23 primary Form 4 filings, an average of 7.7 per year. 59 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
